Daniel P. O’Day
Chairman And Chief Executive Officer
Gilead Sciences, Inc. · GILD
$28.4M
Reported total · FY2025 · SCT Total as filed
Source: DEF 14A filed March 20, 2026. Prior years are from that filing's three-year table.
Catalog as of September 15, 2026. Not a live market feed.
- Salary
- $1.8M
- Stock Awards
- $15.2M
- Option Awards
- $4.5M
- Incentives
- $4.8M
- Other
- $2.1M
Compensation History
| Fiscal Year | Salary | Stock Awards | Total Compensation |
|---|---|---|---|
| 2025 | $1,795,192 | $15,238,402 | $28,437,198 |
| 2024 | $1,771,201 | $12,426,816 | $23,689,392 |
| 2023 | $1,740,962 | $11,865,090 | $22,607,690 |
Current Position
- Company
- Gilead Sciences, Inc.
- Title
- Chairman And Chief Executive Officer
- Ticker
- GILD · NASDAQ
- Fiscal Year
- 2025
SEC Sources
Fiscal years below are columns from the latest DEF 14A Summary Compensation Table (filed March 20, 2026), not separate historical filings.
| Fiscal Year | Source |
|---|---|
| 2025 | View SEC filing |
| 2024 | View SEC filing |
| 2023 | View SEC filing |
Accession 0001308179-26-000106.
Other Gilead Executives
Andrew D. Dickinson
Chief Financial Officer
Gilead · GILD
$8.8M
FY 2025 · DEF 14A
Johanna Mercier
Chief Commercial And Corporate Affairs Officer
Gilead · GILD
$9.3M
FY 2025 · DEF 14A
Dietmar Berger
M.D., Ph.D. Chief Medical Officer
Gilead · GILD
$13.9M
FY 2025 · DEF 14A
Deborah H. Telman
Former Executive Vice President, Corporate Affairs And General Counsel
Gilead · GILD
$5M
FY 2025 · DEF 14A